Latest news and press releases about Century Therapeutics, Inc. (IPSC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments.
Price
| Price | $1.86 |
| Market Cap | $161M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.54 |
| EV / EBITDA | -1.61 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -52.76% |
| Return on Invested Capital | -43.66% |
| Return on Assets | -38.25% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: COEP · CUE · EQ · GNTA · KPTI · MDCX · OSTX
Explore sector: Healthcare · Biotechnology
More sections of IPSC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks